Home/Biosimilar Atlas/Somatropin/Reliance Life Sciences somatropin

Reliance Life Sciences somatropin

Somatropin biosimilar developed by Reliance Life Sciences. Reference product Genotropin (Omnitrope's reference); also Norditropin, Humatrope, Saizen.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Reliance Life Sciences · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOMay 2018permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
SomatropinmoleculeReliance Life Sciencesdeveloper1 of 7markets0trials behind it13other products, same developer4rival developers in its markets

About Reliance Life Sciences somatropin

Reliance Life Sciences received its somatropin permission in India in May 2018, for growth failure in children and hormone deficiency in adults, the second domestic maker after USV.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Reliance Life Sciences Pvt Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
May 2018
Application or permission
MF-145/2018; BULK-146/2018
Indications as licensed
Growth failure in children including small for gestational age; growth hormone deficiency
Presentations
Injection
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Reliance Life Sciences somatropin holds an approval, these are the other somatropin biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO4LG Chem (LG Life Sciences somatropin), Not stated in the CDSCO list (Cipla somatropin), SciGen (SciGen somatropin), USV (USV somatropin)

Same developer, other molecules

Other biosimilars in the Atlas developed by Reliance Life Sciences: Reliance Life Sciences adalimumab, Reliance Life Sciences bevacizumab, Reliance Life Sciences darbepoetin alfa, Reliance Life Sciences denosumab, Reliance Life Sciences etanercept, Reliance Life Sciences follitropin alfa, Reliance Life Sciences golimumab, Reliance Life Sciences infliximab, Reliance Life Sciences omalizumab, Reliance Life Sciences ranibizumab, Reliance Life Sciences rituximab, Reliance Life Sciences trastuzumab, UstekiRel.

Chronology

Sources

All somatropin biosimilars

Planning somatropin biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.